Compare VRTX & EPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTX | EPD |
|---|---|---|
| Founded | 1989 | 1968 |
| Country | United States | United States |
| Employees | N/A | 7300 |
| Industry | EDP Services | Natural Gas Distribution |
| Sector | Technology | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 80.7B |
| IPO Year | 2006 | N/A |
| Metric | VRTX | EPD |
|---|---|---|
| Price | $477.08 | $36.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 14 |
| Target Price | ★ $539.69 | $38.50 |
| AVG Volume (30 Days) | 1.2M | ★ 2.7M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 5.67% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 4.02 | N/A |
| Revenue | ★ $2,488,652,000.00 | N/A |
| Revenue This Year | $10.79 | $2.34 |
| Revenue Next Year | $10.47 | $6.35 |
| P/E Ratio | $118.22 | ★ $13.59 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $362.50 | $30.01 |
| 52 Week High | $509.98 | $40.17 |
| Indicator | VRTX | EPD |
|---|---|---|
| Relative Strength Index (RSI) | 67.93 | 40.10 |
| Support Level | $420.66 | $35.97 |
| Resistance Level | $486.26 | $38.57 |
| Average True Range (ATR) | 11.45 | 0.62 |
| MACD | 3.45 | -0.08 |
| Stochastic Oscillator | 91.58 | 18.40 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Enterprise Products Partners is a master limited partnership that transports and processes natural gas, natural gas liquids, crude oil, refined products, and petrochemicals. It is one of the largest midstream companies, with operations servicing most producing regions in the continental US. Enterprise is particularly dominant in the NGL market and is one of the few MLPs that provide midstream services across the full hydrocarbon value chain.